NFKB1 and non-small cell lung carcinoma: KRAS mutated tumors activate NF-κB p65 pathway to produce anti-apoptotic signals38 and inhibition of NF-kB p65 activation sensitized NSCLC to chemotherapy-induced apoptosis39.